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In the United States, two types of vaccines are recommended for the
prevention of inﬂuenza: an intranasal live attenuated inﬂuenza
vaccine (LAIV) for eligible individuals aged 2–49 years and
unadjuvanted injectable trivalent inactivated vaccines (TIV) for
eligible individuals aged ‡6 months. Several recent studies have
compared the efﬁcacy of the 2 vaccines in children and adults. In
children 6 months to 18 years of age, each of the four comparative
studies of LAIV and TIV demonstrated that LAIV was more
protective. In individuals 17–49 years of age, most comparative
studies have demonstrated that LAIV and TIV were similarly
efﬁcacious or that TIV was more efﬁcacious. However, LAIV was
shown to be more protective than TIV in new military recruits of all
ages, and placebo-controlled studies in adults in 1997–1998
suggested that LAIV was more protective against the mismatched
A⁄H3N2 strain. The relative efﬁcacy of LAIV and TIV among young
adults may vary depending on the speciﬁc population and the
antigenic match between the vaccines and circulating strains. In
adults 60 years of age and older, limited data suggest that the two
vaccines are similarly effective. In children and adults, studies also
suggest that the relative efﬁcacy of LAIV versus TIV may increase
when measured against more severe illness. Additional research
comparing LAIV and TIV is needed in adults and would also be
valuable in older children and adolescents. Studies should examine
the role of pre-existing immunity as well as vaccine impact on
inﬂuenza illness of varying severity.
Keywords Adults, inactivated inﬂuenza vaccine, inﬂuenza, live
attenuated inﬂuenza vaccine, pediatrics.
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Introduction
Vaccination is universally accepted as the most effective
strategy for the prevention of inﬂuenza.
1 In the United
States, two types of vaccines are available: a live, attenu-
ated, intranasal inﬂuenza vaccine (LAIV) and unadjuvanted
trivalent inactivated inﬂuenza vaccines (TIV) for intramus-
cular administration. LAIV is approved for eligible individ-
uals 2–49 years of age. TIV indications have no upper age
limit; lower age limits vary by manufacturer, with some
approved for children as young as 6 months.
1
Understanding the relative efﬁcacy of inﬂuenza vaccines
in various populations is critical to their optimal use. The
ﬁrst priority must be to ensure that as many individuals as
possible are vaccinated. For this reason, the availability of
both LAIV and TIV is valuable because of individual prefer-
ences regarding administration route, side effects, and other
factors. However, a secondary objective should be to direct
individuals to the vaccine that will provide them and poten-
tially their contacts with optimal protection against inﬂu-
enza. The efﬁcacy of inﬂuenza vaccines can vary with the
age of the vaccine recipient and possibly other factors. This
review summarizes recent studies comparing the relative
efﬁcacy of LAIV and TIV in children and adults to facilitate
provider and policymaker decisions regarding optimal vac-
cination strategies for the prevention of inﬂuenza.
Relative efﬁcacy of LAIV and TIV in
children aged 6 months–18 years
Studies directly comparing LAIV and TIV against
natural infection with inﬂuenza
The relative protection provided by LAIV and TIV in chil-
dren was ﬁrst evaluated in 2 studies conducted in 2002–
2003 in Europe and Israel (Figure 1, Table 1).
2,3 Ashkenazi
et al.
2 compared 2 doses of LAIV or TIV in a multina-
tional, randomized, open-label study in 2187 children
6–71 months of age with a history of recurrent respiratory
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to, common colds, acute otitis media, bronchitis, pneumo-
nia, and bronchiolitis; recurrence was deﬁned as ‡2 practi-
tioner-attended RTIs in the previous 12 months. Treatment
groups were well matched with respect to baseline charac-
teristics, including the proportion of children with a history
of wheezing in the prior 12 months (34–36%) or asthma
(23%). There were 53% (95% CI: 22, 72) fewer culture-
conﬁrmed inﬂuenza cases caused by vaccine-matched
strains among recipients of LAIV compared with recipients
of TIV (24⁄1050 versus 50⁄1035, respectively). In a post
hoc analysis, efﬁcacy was shown to be consistent across age
groups.
4 In the study’s evaluation of health outcomes
related to all-cause respiratory illness (i.e. inﬂuenza and
non-inﬂuenza), LAIV recipients reported 9% (95% CI: 2,
16) fewer health care provider visit days and 16% (95% CI:
10, 22) fewer missed days from school or child care com-
pared with TIV recipients. In addition to the greater reduc-
tion in inﬂuenza in LAIV recipients, the severity of
breakthrough inﬂuenza illness was reduced among LAIV
recipients. In post hoc analyses, LAIV recipients with
breakthrough inﬂuenza were more frequently afebrile
(LAIV, 26%; TIV, 5%; P =0 Æ005), missed 1Æ5 (95% CI: 2Æ9,
0Æ2) fewer days of school or daycare (LAIV, 1Æ6 days; TIV,
3Æ1 days; P =0 Æ025), and had less antibiotic use (LAIV,
17%; TIV, 33%; P =0 Æ14).
Concurrently, Fleming et al.
3 evaluated a single dose of
LAIV or TIV in a randomized, multinational, open-label
trial in 2229 children 6–17 years of age with a prior clinical
diagnosis of asthma (Figure 1, Table 1). Children with seri-
ous chronic disease, altered immune function, and those
on immunosuppressive therapy, including high-dose sys-
temic corticosteroids (‡2m g⁄kg per days or ‡20 mg⁄days
of prednisolone or its equivalent), were excluded. However,
in each treatment group, current inhaled steroid use was
reported in 69% of participants and 43% had a history of
systemic steroid treatment.. LAIV recipients experienced
35% (95% CI: 4, 56) fewer cases of inﬂuenza caused by
matched strains than TIV recipients (46⁄1109 versus
70⁄1102, respectively). The relative efﬁcacy of LAIV versus
TIV was similar for children 6–11 and 12–17 years of age.
4
Unlike the observations by Ashkenazi et al.
2, there were no
signiﬁcant differences for other outcome measures (e.g.
health care provider visits, medication use, and days missed
from school or work) or in illness severity between LAIV
and TIV recipients who developed breakthrough inﬂuenza.
In 2004–2005, Belshe et al.
5 compared LAIV and TIV in
a multinational, randomized, double-blind study in 8352
children 6–59 months of age (Figure 1, Table 1). Children
without prior inﬂuenza vaccination were given two doses
of vaccine and those previously vaccinated were given one
dose. Study groups were well matched with respect to
demographic characteristics, including history of prior
inﬂuenza vaccination (22–23%), history of wheezing
(21–22%), recurrent wheezing (6–7%), and asthma (4%).
The primary endpoint was the incidence of culture-
conﬁrmed modiﬁed Centers for Disease Control and
Prevention (CDC) inﬂuenza-like illness (ILI), deﬁned as
fever plus ‡1 other symptom of cough, sore throat, or runny
nose⁄nasal congestion. There were 45% (95% CI: 22, 61)
fewer cases of inﬂuenza caused by matched strains in LAIV
recipients than TIV recipients (53⁄3916 versus 93⁄3936,
respectively), and 58% (95% CI: 47, 67) fewer cases caused
by mismatched strains (102⁄3916 versus 245⁄3936, respec-
tively). Efﬁcacy was consistent across age groups.
4 Similar to
the observation by Ashkenazi et al.
2, breakthrough illness
was less severe among LAIV recipients than TIV recipients.
In a post hoc analysis of any symptomatic inﬂuenza illness
(regardless of whether fever was present), more LAIV recipi-
ents with breakthrough inﬂuenza were afebrile (22% versus
12%, respectively; P =0 Æ001)
6.
Studies comparing LAIV and TIV against inﬂu-
enza-like illness
A large, open-label, non-randomized trial was conducted
by Piedra et al.
7 in the United States during the 2003–2004
inﬂuenza season (Figure 1, Table 1). The study demon-
strated that LAIV was effective in preventing medically
attended, acute respiratory illness among children 5–18
years of age when the mismatched A⁄Fujian⁄411⁄02
(H3N2) virus predominated,
7 whereas no effectiveness was
seen for TIV. LAIV efﬁcacy against inﬂuenza was estimated
at 56% (95% CI: 32, 75), and efﬁcacy was similar for chil-
dren 5–9 and 10–18 years of age.
7,8 However, the direct
comparison of LAIV and TIV in this study should be inter-
preted with caution as the non-randomized LAIV and TIV
groups differed in their baseline characteristics.
Relative efﬁcacy of LAIV and TIV in
individuals aged 17–49 years
Studies comparing LAIV and TIV against
experimental challenge with inﬂuenza
The relative protection provided by LAIV and TIV in
adults was ﬁrst evaluated by Treanor et al.
9 in a placebo-
controlled, double-blind wild-type challenge study in 92
adult volunteers 18–45 years of age (Figure 1, Table 1).
Subjects with baseline serum hemagglutination-inhibition
(HAI) antibody titers of £1:8 to the vaccine strains were
randomized to receive LAIV, TIV, or placebo and chal-
lenged intranasally with 1 vaccine-like wild-type virus
(A⁄H1N1, A⁄H3N2, or B) approximately 28 days later. The
primary objective was to evaluate protection against docu-
mented inﬂuenza, deﬁned as viral shedding (evaluated daily
for 7 days after challenge) and⁄or ‡4-fold increase in HAI
titer (28 days after challenge) in the presence of respiratory
Ambrose et al.
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occurred in 45% (14⁄31) of placebo recipients following
wild-type virus challenge, compared with 6Æ9% (2⁄29) and
12Æ5% (4⁄32) of those given LAIV and TIV, respectively
(P =0 Æ001 for LAIV versus placebo; P =0 Æ006 for TIV ver-
sus placebo; P =0 Æ67 for LAIV versus TIV). Protective efﬁ-
cacy was 85% (95% CI: 28, 100) for LAIV and 71% (95%
CI: 2, 97) for TIV. There were trends toward less severe ill-
ness among LAIV recipients compared with TIV recipients
and less severe illness in both vaccinated groups compared
with placebo recipients. LAIV vaccinees had a lower mean
symptom score than TIV and placebo recipients
(mean ± SE: 2Æ7±1 Æ3, 5Æ7±1 Æ3, 9Æ2±1 Æ3, respectively;
P =0 Æ002 for LAIV versus placebo, P =0 Æ12 for TIV versus
placebo, P =0 Æ24 for LAIV versus TIV). Similarly, 28% of
LAIV and 38% of TIV recipients experienced respiratory
symptoms on consecutive days, compared with 61% of pla-
cebo recipients (P =0 Æ009 for LAIV versus placebo,
P =0 Æ035 for TIV versus placebo).
Studies comparing LAIV and TIV against natural
infection with inﬂuenza
During the 2004–2005, 2005–2006, and 2007–2008 inﬂuenza
seasons, University of Michigan researchers conducted a
multiyear study on state campuses to compare the efﬁcacy
of a single dose of LAIV or TIV in healthy adults 18–
49 years of age (Figure 1, Table 1).
10–12 Each season, only
43%, 30%, and 22% of participants were ‡25 years of age,
respectively. The studies were randomized, placebo-con-
trolled, and double-blind for vaccine versus placebo but
open-label for nasal spray versus injection. During 2004–
2005, the predominant circulating strain was a drifted
A⁄H3N2 strain. Depending on whether culture, PCR, or
both were used to detect inﬂuenza, the observed efﬁcacies
were 48–57% for LAIV and 74–77% for TIV; the difference
between LAIV and TIV was not statistically signiﬁcant.
11
During 2005–2006, the inﬂuenza attack rate observed in the
placebo group was much lower than in 2004–2005 (1Æ8%
versus 7Æ8%), rendering the trial underpowered to detect
vaccine efﬁcacy.
12 Depending on the detection method, the
absolute efﬁcacies ranged from 8–61% for LAIV and 16–
23% for TIV and were statistically similar. During 2007–
2008, when there was signiﬁcant inﬂuenza activity caused
predominantly by a minor antigenic variant A⁄H3N2
strain,
10 the absolute efﬁcacy was 36–51% for LAIV and 68–
73% for TIV. The relative efﬁcacy of TIV versus LAIV was
45% (95% CI: 3, 69) using viral culture and 50% (95% CI:
20, 69) using PCR. No analysis of illness severity among
breakthrough cases was reported for any study season.
Studies comparing LAIV and TIV against inﬂu-
enza-like illness
Since 2004, the United States military has used large
amounts of LAIV and TIV with the goal of vaccinating all
personnel annually; LAIV use increased from 34% of vacci-
nations in 2004–2005 to 48% in 2006–2007 (Figure 1,
Table 1).
13 The extensive use of both vaccines has enabled
retrospective, non-randomized, observational effectiveness
studies of ILI using US military databases. As noted for
Piedra et al.
7, the direct comparison of LAIV and TIV in
Ashkenazi
Belshe
Fleming
Piedra/Halloran*
Ohmit 2006
Ohmit 2008
Monto
Wang, all*
Wang, recently unvaccinated*
Eick, recruits*
Eick, non-recruits*
Treanor†
Forrest
0·1 1 10
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Incidence rate ratio
Figure 1. Incidence Rate Ratios from Studies
Directly Comparing LAIV and TIV in Children
and Adults. LAIV, live attenuated inﬂuenza
vaccine; TIV, trivalent inactivated inﬂuenza
vaccine. Halloran et al., Wang et al., and Eick
et al. should be interpreted with caution as
the non-randomized LAIV and TIV groups
differ in baseline characteristics. For Wang
et al. and Eick et al., a range across study
years and cohorts is displayed for the point
estimate; published incidence rate ratios for
Wang were inverted to represent LAIV⁄TIV.
*Effectiveness studies,
 Challenge study. Data
sources: Ashkenazi et al.
2; Belshe et al.
5;
Fleming et al.
3; Halloran et al.
8; Ohmit
et al.
11; Ohmit et al.
12; Monto et al.
10; Wang
et al.
13; Eick et al.
14; Treanor et al.
9; Forrest
et al.
17.
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non-randomized LAIV and TIV groups may have differed
in their baseline characteristics. Wang et al.
13 conducted a
retrospective cohort study for non-recruit service members
17–49 years of age who received LAIV or TIV during
2004–2005, 2005–2006, or 2006–2007. A multivariate Pois-
son regression model and propensity-based matching were
used to control for covariates such as age, sex, service
branch, medical encounter history, and immunization his-
tory. Because laboratory conﬁrmation of inﬂuenza was not
available, the outcome of interest was the ﬁrst medical
encounter with a diagnosis code associated with pneumo-
nia or inﬂuenza. The incidence rate was highest for the
unimmunized groups and lower in the TIV cohort than in
the LAIV cohort during each season. Adjusted incidence
rate ratios (IRRs) for LAIV-vaccinated versus TIV-vacci-
nated subjects ranged from 1Æ25 to 1Æ75. Among individuals
for whom there was no database record of inﬂuenza vacci-
nation in the previous 1 or 2 seasons since 2004–2005, ILI
incidence was similar among the LAIV and TIV cohorts.
A subsequent analysis by the same investigative group
evaluated protection by LAIV and TIV in military recruits
and non-recruits during 2005–2006 and 2006–2007
(Figure 1, Table 1).
14 Similar to Wang et al.
13, an ICD-9
code deﬁnition of ILI was used. However, the deﬁnitions
differ, with Eick et al.
14 using diagnoses demonstrated to
be associated in the US military population with culture-
conﬁrmed inﬂuenza; diagnoses attributed to other
pathogens were excluded. In contrast to Wang et al.
13, the
regression model included geographic region as a confound-
ing variable, multiple ILI events were included per indivi-
duals, and results were calculated by age category. Among
non-recruits, TIV recipients had a lower incidence of ILI;
adjusted IRRs for LAIV versus TIV were 1Æ17 and 1Æ25–1Æ33
in 2005–2006 and 2006–2007, respectively. When analyzed
by age, IRRs were 1Æ42–1Æ53 among 17- to 19-year-olds and
steadily decreased in older cohorts to 1Æ0–1Æ1 among 40- to
49-year-olds. Among recruits, disease incidence rates were
2–16 times higher than among non-recruits. The LAIV
cohort had a lower incidence of ILI during both seasons
with adjusted IRRs of 0Æ49–0Æ78 and 0Æ53–0Æ82 for 2005–
2006 and 2006–2007, respectively. Adjusted IRRs were not
reported by age group for recruits, but crude incidence rates
suggest that IRRs were similar in recruits of all ages.
Studies conducted in the same inﬂuenza season
comparing LAIV and TIV with placebo against
inﬂuenza-like illness
Two placebo-controlled studies, one involving LAIV and
one involving TIV, conducted in 1997–1998 provide an
additional comparison of the two vaccines in adults.
15,16
The ﬁrst study evaluated the effectiveness of LAIV in
reducing febrile illness in a randomized, double-blind, pla-
cebo-controlled trial of 4561 healthy, working adults 18–
64 years of age.
16 There was no laboratory conﬁrmation of
inﬂuenza. During 1997–1998, the predominant circulating
strain was A⁄Sydney⁄05⁄97 (H3N2), a drifted variant of
the A⁄Wuhan⁄359⁄95 (H3N2) vaccine strain. There was a
19% (95% CI: 7, 29) reduction in severe febrile illness and
a 24% (95% CI: 13, 33) reduction in febrile upper respira-
tory illness among LAIV recipients. There was a limited
sample size of 50- to 64-year-olds (N = 641), and effective-
ness was not demonstrated in this age group in a post hoc
analysis. The second study, conducted by the CDC in
1997–1998, evaluated the effectiveness of TIV in a similar
population of 1184 healthy, working adults 18–64 years of
age.
15 No effectiveness for TIV was observed; presumably,
this was because of TIV’s reduced efﬁcacy against mis-
matched strains, because effectiveness was demonstrated in
the second-season of this same study when matched strains
circulated.
15
Relative efﬁcacy of LAIV and TIV in adults
‡60 years of age
Although LAIV is not currently approved in the United
States in adults ‡50 years of age, several studies have been
conducted and results from these studies are presented here
for completeness.
Studies comparing LAIV and TIV against natural
infection with inﬂuenza
A randomized comparative study of LAIV and TIV con-
ducted in 3009 adults ‡60 years of age did not yield mean-
ingful results because of the low incidence of inﬂuenza
during the 2002 season in South Africa (Figure 1, Table 1)
17
The incidence of conﬁrmed inﬂuenza illness caused by clo-
sely matched strains was 0Æ8 and 0Æ5% in LAIV and TIV
recipients, respectively (12⁄1494 versus 8⁄1488); the relative
efﬁcacy for LAIV versus TIV was )49% (95% CI: )259,
35). A mismatched, opposite-lineage inﬂuenza B strain also
circulated, and there was a similar incidence of this strain
in each treatment group (9⁄1494 versus 5⁄1488). Among
individuals with breakthrough inﬂuenza illness, there were
trends toward less feverishness (LAIV, 14%; TIV, 46%;
P =0 Æ05) and less fever (LAIV, 9%; TIV, 31%; P =0 Æ16) in
LAIV recipients.
Studies comparing LAIV and TIV with placebo
against natural infection with inﬂuenza
Given the inconclusive results from the direct comparison
of LAIV and TIV in older adults, data from placebo-con-
trolled studies were also reviewed. Only two prospective,
randomized, placebo-controlled studies of inﬂuenza vaccine
have been conducted in adults ‡60 years of age, one with
TIV and one with LAIV.
18,19 LAIV and TIV performed
Ambrose et al.
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placebo was conducted in 3242 adults ‡60 years of age and
demonstrated 42% efﬁcacy against inﬂuenza illness caused
by strains matched to the vaccine; 53% efﬁcacy was
observed against A⁄H3N2 strains, with no efﬁcacy against
illness caused by inﬂuenza B.
18 Govaert et al.
19 conducted a
placebo-controlled study of TIV in 1838 subjects and dem-
onstrated a 50% reduction in serologically conﬁrmed inﬂu-
enza infection with TIV and a 27–47% reduction in
various ILI deﬁnitions. Interpretation of this study is com-
plicated by the lack of culture-conﬁrmation of inﬂuenza ill-
ness, because serologic endpoints can fail to detect
breakthrough illness among TIV recipients to a greater
extent than placebo or LAIV recipients.
11,20 Post hoc analy-
ses of these studies found different effects of age on vaccine
efﬁcacy. For the TIV study, efﬁcacy trended lower in those
‡70 years of age, whereas in the LAIV study, efﬁcacy
trended higher in those ‡70 years of age. However, these
trends should be interpreted with caution as they could be
the result of chance alone.
Studies comparing LAIV and TIV in combination
against natural infection with inﬂuenza
The efﬁcacy of LAIV in simultaneous combination with
TIV has also been studied in older adults. In a double-
blind, randomized trial conducted in nursing home resi-
dents aged ‡65 years, 523 residents received TIV and at the
same visit either monovalent A⁄H3N2 LAIV or intranasal
placebo.
21 TIV + LAIV recipients experienced 61% (95%
CI: 18, 82) fewer cases of laboratory-documented inﬂuenza
A compared with those who received TIV+placebo. In a
subsequent study of 2215 individuals ‡50 years of age with
chronic obstructive pulmonary disease, the relative efﬁcacy
of TIV plus trivalent LAIV compared with TIV plus pla-
cebo in the prevention of laboratory-documented inﬂuenza
illness was 16% (95% CI: )22, 43) for any inﬂuenza
strain.
22 It was subsequently noted that TIV + LAIV recipi-
ents had improved chronic lung disease severity index
scores over the course of the study.
23
Safety of LAIV and TIV
Prospective comparative studies of LAIV and TIV have
generally demonstrated comparable safety of the two vac-
cines among individuals ‡2 years of age; most adverse
effects from either vaccine are mild, transient, and of mini-
mal clinical signiﬁcance.
2,3,5,10–12,17 LAIV has been associ-
ated with increased rates of runny nose⁄nasal congestion in
all ages
2,3,5,10–12,17; low-grade fever and decreased appetite
in children aged <6 years;
2,5 and sore throat, cough, and
headache in adults.
11,12,17 TIV has been associated with
increased rates of injection site reaction
2,3,5,10–12,17 in all
ages and fever, muscle aches, and oculorespiratory syn-
drome in adults.
12,24 Although in the United States, LAIV
is not recommended for use in individuals with high-risk
underlying medical conditions, some data exist in these
populations. In asthmatic children 6–17 years of age, there
was a statistically signiﬁcant reduction in wheezing through
15 days post-vaccination among LAIV versus TIV recipi-
ents (19Æ5% versus 23Æ8%, respectively; P =0 Æ02); no other
signiﬁcant differences in asthma symptoms were observed.
3
Additionally, among 243 HIV-infected children 5–17 years
of age receiving stable antiretroviral therapy (viral load
<60 000 and CD4 count >15%), there were no unexpected
toxicities, prolonged shedding, or serious adverse events
associated with either LAIV or TIV.
25 Among individuals
‡50 years of age with chronic obstructive pulmonary dis-
ease, TIV + LAIV recipients reported higher rates of
increased sputum, runny nose⁄nasal congestion, increased
shortness of breath, chills, and itchiness at the intramuscu-
lar injection site compared with TIV+placebo recipients.
22
In one study, an increased rate of medically signiﬁcant
wheezing (MSW) and hospitalization was associated with
LAIV in children <24 months of age.
5 The incidence of
MSW was analyzed through 42 days after vaccination with
LAIV or TIV; MSW was deﬁned as a medical diagnosis of
wheezing associated with other respiratory ﬁndings (e.g.
hypoxemia, respiratory distress, or initiation of daily bron-
chodilator therapy). Among children 6–23 months of age,
5Æ9% of LAIV recipients and 3Æ8% of TIV recipients experi-
enced MSW (P =0 Æ002). For children aged 24–59 months,
rates of MSW were comparable in LAIV and TIV recipients
(LAIV, 2Æ1%; TIV, 2Æ5%; P =0 Æ38). A review of the inci-
dence of MSW by single-month age cohorts revealed
increased rates among LAIV recipients 6–23 months of age,
with no pattern of increase for children 24–59 months of
age.
26 In this same study, all-cause hospitalization rates
through 180 days post-vaccination were higher among
LAIV recipients than TIV recipients 6–11 months of age
(LAIV, 6Æ1%; TIV, 2Æ6%; P =0 Æ002); no increase was seen
with LAIV in children 12–59 months of age. Based on these
observations, LAIV is not approved for use in children
<24 months of age.
Conclusions
In all age groups studied, LAIV and TIV were effective in
preventing inﬂuenza illness. In children, all four compara-
tive studies of LAIV and TIV demonstrated that LAIV was
more protective against culture-conﬁrmed inﬂuenza illness
in children 6 months to 17 years of age.
2,3,5,7 These results
are supported by the results of studies that have compared
the vaccines to placebo. A meta-analysis of six placebo-
controlled studies of LAIV calculated that the mean efﬁcacy
of two doses against matched strains of all subtypes in pre-
viously unvaccinated young children was 77% (95% CI: 72,
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27; the mean efﬁcacy of 1 dose of LAIV in previously
vaccinated children was 87% (95% CI: 81, 90).
27 Three sep-
arate meta-analyses of the efﬁcacy of TIV against labora-
tory-conﬁrmed inﬂuenza in children compared with
placebo calculated that the mean efﬁcacy of TIV against
matched strains was 59% (95% CI: 41, 71),
28 63% (95%
CI: 45, 70),
29 and 65% (95% CI: 45, 77).
30 Studies also
indicate that the efﬁcacy difference between LAIV and TIV
in children increases with circulation of antigenically mis-
matched strains. As noted previously, LAIV is approved for
eligible children 2–17 years of age because of an observed
increased rate of medically attended wheezing in children
6–23 months of age.
In contrast, most comparative studies in individuals
17–49 years of age have demonstrated that LAIV and TIV
were similarly efﬁcacious or that TIV was more efﬁcacious.
A randomized, culture-conﬁrmed ﬁeld trial conducted
during three inﬂuenza seasons demonstrated that TIV was
more efﬁcacious than LAIV in healthy adults,
10–12
with a statistically signiﬁcant difference demonstrated in
2007–2008.
10 Retrospective effectiveness studies of inﬂu-
enza-like illness in the US military have demonstrated sim-
ilar results in their overall population.
13 However, in the
US military studies, LAIV was more protective than TIV
against inﬂuenza-like illness in new recruits of all ages and
similarly effective in older non-recruits.
14 Additionally,
studies conducted in 1997–1998 suggested that LAIV was
more protective against the circulating mismatched
A⁄H3N2 strain.
15,16 Among individuals 17–49 years of age,
the relative efﬁcacy of LAIV and TIV appear to vary
depending on the speciﬁc population studied, the type of
study, and the degree of antigenic match between the
study vaccines and circulating strains. Among adults
‡60 years of age, the limited available data suggest that
the two vaccines are similarly effective. However, as
noted previously, because of limited data, LAIV is not
currently approved in the United States in adults ‡50 years
of age.
Both LAIV and TIV can induce priming immune
responses and boost pre-existing anti-inﬂuenza immunity.
However, LAIV appears to be more effective than TIV as
a priming vaccine, and TIV appears to be more effective
in boosting pre-existing immunity.
31,32 Given the annual
changes in circulating strains of inﬂuenza, both types of
immune responses are important for individuals of all
ages. However, these differential mechanisms of action
may explain the differential relative efﬁcacy of LAIV and
TIV in children and young adults. TIV efﬁcacy may be
higher in adult versus pediatric populations because adults
have greater immunologic priming from multiple previous
natural infections with inﬂuenza. Conversely, it has been
suggested that LAIV efﬁcacy may decline in adults because
higher pre-existing anti-inﬂuenza immunity may limit
intranasal replication of LAIV.
10,11 However, an analysis
of multiple efﬁcacy studies conducted in children
6 months to 17 years of age found no evidence of a
decline in LAIV efﬁcacy with increased age or with
increased pre-existing immunity to inﬂuenza within this
age range.
4 In adults, no evidence has been published to
directly support this hypothesis; post hoc analyses of com-
pleted studies in adults should be conducted to examine
this issue.
Variations in the severity of the inﬂuenza illness mea-
sured in a study may inﬂuence relative efﬁcacy estimates.
As noted earlier and in the Table 1, studies have demon-
strated that LAIV-vaccinated children and adults who
develop inﬂuenza illness tend to have less severe illness
than TIV-vaccinated individuals, perhaps because of
enhanced mucosal or cellular immunity. As a result, the
relative efﬁcacy of LAIV versus TIV in children and
adults may increase when measured against more severe
illness. The impact of breakthrough illness severity on
LAIV and TIV efﬁcacy should be evaluated in future
studies and through post hoc analyses of completed stud-
ies.
The primary limitation of the current analysis is the
small number of prospective, randomized studies. Inﬂuenza
vaccine efﬁcacy studies that are appropriately powered to
compare two effective vaccines require large numbers of
subjects and are very costly. As a result, it is not surprising
that few have been conducted. Additionally, given the
annual variation in both circulating strains and the inﬂu-
enza attack rate, consistent results across multiple seasons
and geographies are needed for robust conclusions. In chil-
dren, particularly younger children, multiple randomized
and observational studies as well as meta-analyses of pla-
cebo-controlled studies have yielded consistent results. In
adults, less data are available and results have been more
variable. To more fully understand the relative beneﬁts of
TIV and LAIV in adults, additional research is needed. A
multi-country, multi-year, double-blind, well-powered
study in individuals ‡18 years of age would be valuable.
Additional studies in older children and adolescents would
also be valuable. These studies should be stratiﬁed so that
relative efﬁcacy can be determined by age group. Multiple
aspects of baseline anti-inﬂuenza immunity should be eval-
uated to elucidate the role of pre-existing immunity, and
various inﬂuenza symptoms should be collected to describe
the impact of LAIV and TIV on inﬂuenza illness of varying
severity.
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